Daniel J Escudero1, Brandon D L Marshall1, Thomas Kerr2, Kanna Hayashi2, Cindy Feng3, Silvia A Guillemi3, Robert S Hogg3, Julio Montaner2, Evan Wood2, M-J Milloy4. 1. Department of Epidemiology, Brown University School of Public Health, 2nd Floor, 121 S. Main St., Providence, RI 02906, United States. 2. British Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Division of AIDS, Department of Medicine, University of British Columbia, 667-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. 3. British Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. 4. British Columbia Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Division of AIDS, Department of Medicine, University of British Columbia, 667-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. Electronic address: uhri-mjsm@cfenet.ubc.ca.
Abstract
BACKGROUND: The evidence to date on whether HIV infection increases the risk of accidental drug overdose among people who inject drugs (PWID) is equivocal. Thus, we sought to estimate the effect of HIV infection on risk of non-fatal overdose among two parallel cohorts of HIV-positive and -negative PWID. METHODS: Data were collected from a prospective cohort of PWID in Vancouver, Canada between 2006 and 2013. During biannual follow-up assessments, non-fatal overdose within the previous 6months was assessed. Bivariable and multivariable generalized mixed-effects regression models were used to determine the unadjusted and adjusted associations between HIV status, plasma HIV-1 RNA viral load, and likelihood of non-fatal overdose. RESULTS: A total of 1760 eligible participants (67% male, median age=42, and 42% HIV-positive at baseline) were included. Among 15,070 unique observations, 649 (4.3%) included a report of a non-fatal overdose within the previous 6months (4.4% among seropositive and 4.3% among seronegative individuals). We did not observe a difference in the likelihood of overdose by HIV serostatus in crude (odds ratio [OR]: 1.05, p=0.853) analyses or analyses adjusted for known overdose risk factors (adjusted OR [AOR]: 1.19, p=0.474). In a secondary analysis, among HIV-positive PWID, we did not observe an association between having a detectable viral load and overdose (AOR: 1.03, p=0.862). CONCLUSIONS: Despite the evidence that HIV infection is a risk factor for fatal overdose, we found no evidence for a relationship between HIV disease and non-fatal overdose. However, overdose remains high among PWID, indicating the need for ongoing policy addressing this problem, and research into understanding modifiable risk factors that predict non-fatal overdose.
BACKGROUND: The evidence to date on whether HIV infection increases the risk of accidental drug overdose among people who inject drugs (PWID) is equivocal. Thus, we sought to estimate the effect of HIV infection on risk of non-fatal overdose among two parallel cohorts of HIV-positive and -negative PWID. METHODS: Data were collected from a prospective cohort of PWID in Vancouver, Canada between 2006 and 2013. During biannual follow-up assessments, non-fatal overdose within the previous 6months was assessed. Bivariable and multivariable generalized mixed-effects regression models were used to determine the unadjusted and adjusted associations between HIV status, plasma HIV-1 RNA viral load, and likelihood of non-fatal overdose. RESULTS: A total of 1760 eligible participants (67% male, median age=42, and 42% HIV-positive at baseline) were included. Among 15,070 unique observations, 649 (4.3%) included a report of a non-fatal overdose within the previous 6months (4.4% among seropositive and 4.3% among seronegative individuals). We did not observe a difference in the likelihood of overdose by HIV serostatus in crude (odds ratio [OR]: 1.05, p=0.853) analyses or analyses adjusted for known overdose risk factors (adjusted OR [AOR]: 1.19, p=0.474). In a secondary analysis, among HIV-positive PWID, we did not observe an association between having a detectable viral load and overdose (AOR: 1.03, p=0.862). CONCLUSIONS: Despite the evidence that HIV infection is a risk factor for fatal overdose, we found no evidence for a relationship between HIV disease and non-fatal overdose. However, overdose remains high among PWID, indicating the need for ongoing policy addressing this problem, and research into understanding modifiable risk factors that predict non-fatal overdose.
Authors: Kristen C Ochoa; Peter J Davidson; Jennifer L Evans; Judith A Hahn; Kimberly Page-Shafer; Andrew R Moss Journal: Drug Alcohol Depend Date: 2005-06-14 Impact factor: 4.492
Authors: Cunlin Wang; David Vlahov; Noya Galai; Stephen R Cole; Joseph Bareta; Robin Pollini; Shruti H Mehta; Kenrad E Nelson; Sandro Galea Journal: AIDS Date: 2005-06-10 Impact factor: 4.177
Authors: M J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood Journal: J Infect Dis Date: 2011-05-01 Impact factor: 5.226
Authors: Thomas Kerr; Nadia Fairbairn; Mark Tyndall; David Marsh; Kathy Li; Julio Montaner; Evan Wood Journal: Drug Alcohol Depend Date: 2006-09-07 Impact factor: 4.492
Authors: Thomas Kerr; Will Small; Chris Buchner; Ruth Zhang; Kathy Li; Julio Montaner; Evan Wood Journal: Am J Public Health Date: 2010-06-17 Impact factor: 9.308
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Sunil S Solomon; David D Celentano; Aylur K Srikrishnan; Canjeevaram K Vasudevan; Santhanam Anand; Muniratnam S Kumar; Suniti Solomon; Gregory M Lucas; Shruti H Mehta Journal: AIDS Date: 2009-05-15 Impact factor: 4.177
Authors: Alexander Y Walley; Debbie M Cheng; Emily K Quinn; Elena Blokhina; Natalia Gnatienko; Christine E Chaisson; Evgeny Krupitsky; Philip O Coffin; Jeffrey H Samet Journal: Int J Drug Policy Date: 2016-11-28
Authors: Brendan P Jacka; Jacqueline E Goldman; Jesse L Yedinak; Edward Bernstein; Scott E Hadland; Jane A Buxton; Susan G Sherman; Katie B Biello; Brandon D L Marshall Journal: Trials Date: 2020-11-26 Impact factor: 2.279